The feasibility and acceptability of collecting psychosocial outcome measures embedded within a precision medicine trial for childhood cancer

Eden G. Robertson,Kate Hetherington,Rebecca Daly,Mark W. Donoghoe,Nicholas Handelsman,David S. Ziegler,Claire E. Wakefield
DOI: https://doi.org/10.1002/cam4.7339
IF: 4.711
2024-06-21
Cancer Medicine
Abstract:Background Patient‐reported outcomes measures (PROMs) are increasingly being collected within cancer clinical trials, yet limited literature on the feasibility and acceptability of doing so. Methods We collected parent‐proxy and adolescent (≥12 years old) PROMs through a longitudinal, psychosocial sub‐study ('PRISM‐Impact') embedded in a precision medicine trial for children with poor prognosis cancer ('PRISM'). We report on feasibility (response, participation, and attrition rates; follow‐up and responding to elevated distress) and acceptability (parents' perceived benefit/burden of participation; and impact on decision to participate in PRISM) of PRISM‐Impact. Results Over the reporting period, 462 families were eligible for PRISM‐Impact. Family and adolescent response rates were 53% and 45%, respectively. Parents whose child had relapsed were more likely to participate in PRISM‐Impact than parents whose child had not (p
oncology
What problem does this paper attempt to address?